MYRIAD GENETICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
Kirby McInerney LLP announced an investigation into potential securities fraud claims against Myriad Genetics, focusing on the company's recent disclosures regarding earnings and reimbursement challenges. The investigation follows a 47% plunge in Myriad's stock price after the company reported an 11% year-over-year revenue decline to $190.7 million and lowered its full-year 2026 guidance to $770-$790 million.
Key figures
- Revenue
- $190.7 million
- Guidance
- $770 to $790 million
- Revenue Yoy
- -11%
- Stock close price
- $2.86
- Stock decline amount
- $2.51
- Stock decline percent
- 47%
- Revenue reduction collection estimates
- $11 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.